Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
Lexaria secures up to $5.9 million from discounted warrant exercises while issuing new warrants that may add future dilution.
Rhea-AI Summary
Lexaria Bioscience (LEXX) entered definitive agreements for the immediate cash exercise of 453,969 outstanding warrants at a reduced exercise price of $12.92 per share. Closing is expected on or about September 9, 2026, subject to customary conditions.
The warrant exercises are expected to generate approximately $5.9 million in gross proceeds before fees, to be used for working capital and general corporate purposes. In exchange, Lexaria will issue new unregistered Series A and Series B warrants for up to 453,969 shares each, both exercisable immediately at $12.67 per share, with five‑year and eighteen‑month terms, respectively, from the effective date of a planned resale registration statement. The CEO also cites a recently received $2.6 million Australian tax rebate as additional funding for 2027 operations and R&D.
Positive
- Gross proceeds ≈$5.9M expected from immediate warrant exercises, before fees
- 453,969 warrants exercised provide near‑term cash without a new public offering
- $2.6M Australian tax rebate recently received adds to available funding for 2027
Negative
- Existing warrant exercise prices cut to $12.92, down from up to $45.90
- Issuance of 907,938 new Series A and B warrants at $12.67 may create future dilution
News Explained
The new warrant tranches create potential future share supply that could reduce existing holders’ ownership percentage if exercised.
The warrant exercise and issuance of the new warrants are not yet complete because closing is expected on or about
The shares issuable upon exercise of the existing warrants are covered by effective registration statements, while the new warrants are unregistered private-placement securities; the agreed resale registration statement is a later registration step rather than a completed sale.
As of
Sources and calculations
- Lexaria warrant exercise release (2026-09-08)
- Dilution definition (undated)
- Private placement / PIPE definition (undated)
- Form S-1 purpose (undated)
- Form S-3 purpose (undated)
- Lexaria latest-quarter fundamentals (2026Q3)
- Available liquidity against the last reported quarterly operating outflow, in days at that rate ($3,500,000 + $142,103) / ($1,635,020 / 92) = 204.9 days
Details
Market reaction after warrant exercise offering: LEXX -19.58%
Following this news, LEXX has declined 19.58%, reflecting a significant negative market reaction. Our momentum scanner has triggered 3 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $11.38. Trading volume is exceptionally heavy at 5.0x the average, suggesting significant selling pressure.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Warrants exercised
- 453,969 shares
- Immediate exercise of outstanding warrants
- Reduced exercise price
- $12.92 per share
- Price for immediate warrant exercise
- Gross proceeds
- $5.9 million
- Before placement agent fees and other offering expenses
- Series A warrants
- 453,969 shares
- New unregistered warrants exercisable immediately
- Series B warrants
- 453,969 shares
- New short-term unregistered warrants exercisable immediately
- New warrant exercise price
- $12.67 per share
- Series A and Series B warrants
- Series A expiration
- Five years
- From the effective date of the Resale Registration Statement
- Series B expiration
- Eighteen months
- From the effective date of the Resale Registration Statement
Previous Offering Reports
-
Company closed a $3.5 million offering with shares and warrants
-
Company announced $3.5 million offering with attached private-placement warrants
-
Company closed $4.0 million offering and issued additional warrants
-
Company announced $4.0 million offering with concurrent warrant placement
-
Company closed $2 million stock offering without additional warrants
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
warrants financial
private placement financial
resale registration statement regulatory
form s-3 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
KELOWNA, BC / ACCESS Newswire / September 8, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exercise price of
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form S-1 (File No. 333-277863), Form S-3 (File No. 333-283484), Form S-1 (File No. 333-290862), and Form S-1 (File No. 333-292469).
In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered Series A warrants to purchase up to an aggregate of 453,969 shares of common stock (the "Series A Warrants") and short-term Series B warrants (the "Series B Warrants," and together with the Series A Warrants, the "New Warrants") to purchase up to an aggregate of 453,969 shares of common stock. The Series A Warrants will have an exercise price of
The gross proceeds to the Company from the exercise of the warrants are expected to be approximately
"We are extremely pleased for the potential
The New Warrants described above are being offered in a private placement and, along with the shares of common stock issuable upon exercise of the New Warrants, have not been registered under the Securities Act of 1933, as amended (the "1933 Act"), or applicable state securities laws. Accordingly, the New Warrants and shares of common stock issuable upon the exercise of the New Warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the 1933 Act and such applicable state securities laws. The Company has agreed to file a registration statement with the Securities and Exchange Commission ("SEC") as soon as practicable covering the resale of the shares of common stock issuable upon exercise of the New Warrants (the "Resale Registration Statement").
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 66 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the satisfaction of customary closing conditions, the intended use of proceeds from the offering, the anticipated closing of the offering, the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext. 202
SOURCE: Lexaria Bioscience Corp.
View the original press release on ACCESS Newswire
FAQ
What are the key terms of Lexaria's new Series A and Series B warrants?
The Series A Warrants allow purchase of up to 453,969 common shares, have an exercise price of $12.67 per share, are exercisable immediately upon issuance and expire five years from the effective date of the resale registration statement. The Series B Warrants cover up to 453,969 shares at the same $12.67 exercise price, are also exercisable immediately and expire eighteen months from the resale registration statement's effective date.
When is the warrant exercise transaction expected to close and who is the placement agent?
The closing of the warrant exercise transaction is expected to occur on or about September 9, 2026, subject to satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.